The Muscular Dystrophy Association (MDA) is highlighting unprecedented scientific progress in amyotrophic lateral sclerosis (ALS) research during ALS Awareness Month in May, while highlighting several promising advances presented at the 2026 MDA Clinical & Scientific Conference in March.
Breakthrough Research Developments
Dr. Bryan Traynor, Senior Investigator at the National Institutes of Health, shared new insights signaling a potential turning point in ALS understanding and treatment. Researchers have identified a set of plasma proteins that can detect ALS with a high degree of accuracy—potentially the first objective method to support ALS diagnosis. Evidence shows that disease-related changes may be detectable up to 10 years before clinical symptoms emerge, which could allow patients to enter clinical trials sooner and potentially benefit from interventions before significant motor neuron loss occurs.
Using large-scale genomic data, researchers are identifying existing drugs that could be repurposed for ALS, helping to accelerate the development of new treatments. Dr. Traynor, who is a recipient of the 2026 Breakthrough Prize in Life Sciences for discovering the most common genetic cause of ALS and frontotemporal dementia, stated that “ALS research is shifting from reacting to symptoms to identifying the disease earlier and targeting it more precisely.”
Current Research Investment and Legislation
MDA’s ongoing investments in ALS research include nearly $2 million awarded in ALS grants in 2025, with 27 active ALS research projects. Over the past five years, MDA has awarded nearly $9 million, with over $180 million invested in research overall. Sharon Hesterlee, PhD, President and CEO of MDA, stated: “Over the past decade, ALS has moved from almost no options to real momentum and growing hope. Scientists now know ALS is not one disease, but many, leading to treatments that can slow progression for some patients.”
This ALS Awareness Month, MDA is calling on Congress to expand access to care, advance research, and improve quality of life. The organization is urging Congress to reauthorize the ACT for ALS before the September 30, 2026 deadline, and to pass the ALS Better Care Act, which would expand Medicare coverage for essential ALS-related services.
Community Programs and Fundraising
MDA will host two free educational programs for people living with ALS and their caregivers, with expert-led presentations on symptom management, mental health, resources, and advocacy. The community can learn about the newest advances in ALS research through an on-demand webinar featuring researchers from the National Institute of Aging and the ALS Therapy Development Institute, available May 29.
The 6th annual MLB Lou Gehrig Day is scheduled for June 2, 2026, with all 30 teams participating and wearing special “4-ALS” patches to honor the Hall of Famer and raise funds for ALS research.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.globenewswire.com/news-release/2026/04/28/3282737/0/en/Muscular-Dystrophy-Association-Marks-ALS-Awareness-Month-throughout-May-with-Breakthrough-Research-Powerful-Stories-and-Nationwide-Call-to-Action-to-End-ALS.html